Zynex, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded net revenues of $13.4 million, a substantial decrease of 73% compared to $50.0 million in the same quarter of 2024. For the nine months ended September 30, 2025, revenues totaled $62.2 million, down 57% from $146.4 million in the prior year. The decline in revenue was attributed primarily to a temporary suspension of payments from the Tricare program, which historically accounted for 20-25% of the company's annual revenue, and a reduction in device orders and supply sales.
The company's net loss for the third quarter was $42.9 million, a stark contrast to a net income of $2.4 million in the same period last year. For the nine-month period, Zynex reported a net loss of $73.3 million, compared to a net income of $3.6 million in 2024. The losses were exacerbated by a $30.7 million impairment charge related to the company's Zynex Monitoring Solutions (ZMS) subsidiary, which was prompted by a strategic shift to seek commercialization partners for its NiCO CO-Oximeter rather than pursuing independent commercialization.
Operationally, Zynex faced challenges with workforce reductions, which impacted device orders and onboarding of new patients. The company reduced its workforce by approximately 15% in early 2025 in response to the Tricare payment suspension and further layoffs in June 2025. However, during the third quarter, Zynex rehired some employees to support service levels, indicating a recognition of the negative impact that previous reductions had on operations.
As of September 30, 2025, Zynex's cash and cash equivalents stood at $13.3 million, down from $39.6 million at the end of 2024. The company also reported a working capital deficit of $41.8 million, primarily due to the reclassification of $60 million in outstanding convertible senior notes to current liabilities. The company has indicated that its existing cash resources may not be sufficient to support operations for the next year, raising concerns about its ability to continue as a going concern. Zynex is currently exploring restructuring options and has retained financial advisors to assist in discussions with creditors regarding its outstanding debt obligations.
Looking ahead, Zynex's management has expressed uncertainty regarding its financial stability and operational viability, particularly in light of ongoing payment suspensions and the need for strategic restructuring. The company has not made an interest payment due on its convertible senior notes, which could trigger an event of default if not resolved within the grace period. The outlook remains cautious as Zynex navigates these significant operational and financial challenges.
About ZYNEX INC
Zynex, Inc. designs and markets medical devices for pain management, rehabilitation, and non-invasive patient monitoring. Its core products include electrotherapy devices, private-labeled supplies, and innovative monitoring systems. Serving healthcare providers and patients primarily in the U.S., the company emphasizes non-invasive, FDA-regulated solutions that reduce reliance on medications and improve patient outcomes through portable, user-friendly technology.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.